Inventor

STRUM JAY COPELAND

US40 patents

⚠️ This page may combine multiple inventors who share the name “STRUM JAY COPELAND”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.

STRUM JAY COPELAND

G1 THERAPEUTICS INC

HSPC-sparing treatments for RB-positive abnormal cellular proliferation

Transient protection of normal cells during chemotherapy

Transient protection of normal cells during chemotherapy

Morphic forms of trilaciclib and methods of manufacture thereof

HSPC-sparing treatments for Rb-positive abnormal cellular proliferation

Transient protection of normal cells during chemotherapy

HSPC-sparing treatments for RB-positive abnormal cellular proliferation

Transient protection of normal cells during chemotherapy

HSPC-sparing treatments for RB-positive abnormal cellular proliferation

Morphic forms of trilaciclib and methods of manufacture thereof

Transient protection of normal cells during chemotherapy

Treatment of Rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors

Transient protection of normal cells during chemotherapy

Transient protection of normal cells during chemotherapy

HSPC-sparing treatments for RB-positive abnormal cellular proliferation

CDK inhibitors

Highly active anti-neoplastic and anti-proliferative agents

CDK inhibitors

Transient protection of normal cells during chemotherapy

Tricyclic lactams for use in HSPC-sparing treatments for Rb-positive abnormal cellular proliferation

Tricyclic lactams for use in HSPC-sparing treatments for RB-positive abnormal cellular proliferation

Treatment of EGFR-driven cancer with fewer side effects

G1T38 superior dosage regimes

Treatment of Rb-negative tumors using topoisomerase with cyclin dependent kinase 4/6 inhibitors

Anti-neoplastic combinations and dosing regimens using CDK4/6 inhibitor compounds to treat RB-positive tumors

Treatment of Rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors

Benzothiophene estrogen receptor modulators

Antiproliferative pyrimidine-based compounds

Benzothiophene estrogen receptor modulators

Pyrimidine-based compounds for the treatment of cancer

Anti-neoplastic combinations and dosing regimens using CDK4/6 inhibitor compounds to treat Rb-positive tumors

Substituted dihydropyrazino[1 ′,2′:1,5]pyrrolo[2,3-d]pyrimidine-based antiproliferative agents

Substituted 1′,2′-dihydro-3′H-spiro[cyclohexane-1,4′-pyrimido[5′,4′:4,5]pyrrolo[2,1-c][1,2,4]triazin]-3′-ones as cyclin-dependent kinase inhibitors

Benzothiophene estrogen receptor modulators

PHARMACOSMOS HOLDING AS

G1T38 superior dosage regimes

Substituted 1′,2′-dihydro-3′h-spiro[cyclohexane-1,4′-pyrimido[5′,4′:4,5]pyrrolo[2,1-c] [1,2,4]triazin]-3′-ones as cyclin-dependent kinase inhibitors

Substituted 1′,2′-dihydro-3′H-spiro[cyclohexane-1,4′-pyrimido[5′,4′:4,5]pyrrolo[2,1-c][1,2,4]triazin]-3′-ones as cyclin-dependent kinase inhibitors

Morphic forms of trilaciclib and methods of manufacture thereof

Morphic forms of trilaciclib and methods of manufacture thereof

Morphic forms of trilaciclib and methods of manufacture thereof